Full Press Release Details
Turn Therapeutics to Present at Jefferies Global
Healthcare Conference 2026
Westlake Village, Calif. - May 19,
2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for
inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare
Conference in New York City as follows:
Time: 9:55AM - 10:25 AM EDT
A live webcast of the presentation may be accessed
on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations.
A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation.
About Turn Therapeutics
Turn Therapeutics is a biotechnology company focused
on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Its lead
investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in development for the treatment of moderate-to-severe
atopic dermatitis. This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological
conditions, specifically targeting IL-36 and IL-31, two cytokines that play distinct but interconnected roles in driving chronic skin
inflammation and the itch-scratch cycle. GX-03 addresses IL-36 upstream, where epithelial stress and barrier disruption initiate the inflammatory
cascade, and IL-31 downstream, where itch signaling perpetuates disease. It is currently being evaluated in a Phase 2 randomized controlled
trial, with topline results expected in mid-2026.
Investor Relations / Media Contact